EP4215525A4 - Dérivé de pipérazine, son procédé de préparation et son utilisation - Google Patents

Dérivé de pipérazine, son procédé de préparation et son utilisation Download PDF

Info

Publication number
EP4215525A4
EP4215525A4 EP21868671.5A EP21868671A EP4215525A4 EP 4215525 A4 EP4215525 A4 EP 4215525A4 EP 21868671 A EP21868671 A EP 21868671A EP 4215525 A4 EP4215525 A4 EP 4215525A4
Authority
EP
European Patent Office
Prior art keywords
preparation process
piperazine derivative
piperazine
derivative
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21868671.5A
Other languages
German (de)
English (en)
Other versions
EP4215525A1 (fr
Inventor
Haibo Qiu
Yutao Ma
Ahuan CHEN
Yabo ZHU
Binhao ZHANG
Yongping LU
Cheng Ye
Taishan HU
Wenjian QIAN
Lei Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd, Shanghai Aryl Pharmtech Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of EP4215525A1 publication Critical patent/EP4215525A1/fr
Publication of EP4215525A4 publication Critical patent/EP4215525A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP21868671.5A 2020-09-17 2021-09-16 Dérivé de pipérazine, son procédé de préparation et son utilisation Pending EP4215525A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010978095 2020-09-17
CN202110597053 2021-05-28
PCT/CN2021/118671 WO2022057849A1 (fr) 2020-09-17 2021-09-16 Dérivé de pipérazine, son procédé de préparation et son utilisation

Publications (2)

Publication Number Publication Date
EP4215525A1 EP4215525A1 (fr) 2023-07-26
EP4215525A4 true EP4215525A4 (fr) 2024-08-21

Family

ID=80776447

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21868671.5A Pending EP4215525A4 (fr) 2020-09-17 2021-09-16 Dérivé de pipérazine, son procédé de préparation et son utilisation

Country Status (5)

Country Link
US (1) US20230373972A1 (fr)
EP (1) EP4215525A4 (fr)
JP (1) JP7700218B2 (fr)
CN (1) CN116348109B (fr)
WO (1) WO2022057849A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2184272A1 (fr) * 2007-08-21 2010-05-12 Shionogi&Co., Ltd. Dérivé de pipérazine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2423902A1 (fr) * 2000-09-27 2003-03-26 Ajinomoto Co., Inc. Derive de benzodiazepine
WO2007070816A2 (fr) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Derives de thiophene en tant qu'inhibiteurs du facteur xia
MX2011000755A (es) 2008-07-28 2011-02-24 Hoffmann La Roche Derivados de diazepan y piperazina moduladores de receptores de quimiocina.
WO2011002067A1 (fr) * 2009-07-02 2011-01-06 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
WO2011016559A1 (fr) * 2009-08-07 2011-02-10 武田薬品工業株式会社 Composé hétérocyclique et son utilisation
JP2017517512A (ja) * 2014-05-28 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 第xia因子インヒビター
CA2959987C (fr) 2014-09-02 2023-05-09 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Composes de pyrazolo[3,4-c]pyridine et leurs effets contre la thrombose
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
ES2754599T3 (es) * 2015-08-05 2020-04-20 Bristol Myers Squibb Co Nuevos inhibidores de FXIa derivados de glicina sustituidos
RU2638155C1 (ru) 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
CN109563092B (zh) * 2016-07-11 2021-09-14 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物
EP3500556B1 (fr) * 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Dérivés pyridine-1-oxyde et leur utilisation en tant qu'inhbiteurs du facteur xia
WO2018089433A1 (fr) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. Inhibiteurs de mtorc phényle et leurs utilisations
US10683297B2 (en) 2017-11-19 2020-06-16 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
CN108863962B (zh) 2018-07-25 2021-08-03 南京农业大学 一种含1-苯基-1,2,3-三氮唑结构的酰胺类化合物及其应用
JP7447089B2 (ja) 2018-08-31 2024-03-11 サイトキネティックス, インコーポレイテッド 心筋サルコメア阻害剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2184272A1 (fr) * 2007-08-21 2010-05-12 Shionogi&Co., Ltd. Dérivé de pipérazine

Also Published As

Publication number Publication date
CN116348109B (zh) 2025-01-21
CN116348109A (zh) 2023-06-27
US20230373972A1 (en) 2023-11-23
JP2023541309A (ja) 2023-09-29
WO2022057849A1 (fr) 2022-03-24
JP7700218B2 (ja) 2025-06-30
EP4215525A1 (fr) 2023-07-26

Similar Documents

Publication Publication Date Title
EP4385989A4 (fr) Dérivé de sulfonamide, son procédé de préparation et son utilisation médicale
EP3967687A4 (fr) Dérivé de phénylpropénylpyridine substitué, son procédé de préparation et son utilisation médicale
EP3750887A4 (fr) Dérivé de biaryle, son procédé de préparation, et son application pharmaceutique
EP3632907A4 (fr) Dérivé de n-(azaaryl)cyclolactame-1-carboxamide, son procédé de préparation et son utilisation
EP3816150A4 (fr) Composé m-diamide, son procédé de préparation et son utilisation
EP3822271A4 (fr) Dérivé de pyridopyrimidine, son procédé de préparation et son utilisation médicale
EP4063363A4 (fr) Dérivé pyrazolo-hétéroaryl, son procédé de préparation et son utilisation médicale
EP4101437A4 (fr) Composition bactériostatique, son procédé de préparation et son utilisation
EP4349815A4 (fr) Dérivé de 7-nitro-8-hydroxyquinoléine, son procédé de préparation et utilisation médicale associée
EP3730491A4 (fr) Dérivé d'isoxazole, son procédé de préparation et son utilisation
EP3812376A4 (fr) Conjugué de type double de paclitaxel-lipide-polysaccharide, son procédé de préparation et son utilisation
EP4056571A4 (fr) Dérivé de dihydroimidazopyrimidone tricyclique, son procédé de préparation, composition pharmaceutique et son utilisation
EP4464312A4 (fr) Oléogel, son procédé de préparation et son utilisation
EP4079734A4 (fr) Dérivé de triazolopyridazine, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante
EP3819292A4 (fr) Dérivé de phtalide, son procédé de préparation et son utilisation
EP3998270A4 (fr) Dérivé alcyne, son procédé de préparation et ses utilisations
EP3660019A4 (fr) Composé, son procédé de préparation et son utilisation
EP3780098A4 (fr) Condensateur et son procédé de préparation
EP3617218A4 (fr) Conjugué dihydroartémisinine-stéroïde, son procédé de préparation et son utilisation
EP4282864A4 (fr) Inhibiteur double cible cdk6/dyrk2, son procédé de préparation et son utilisation
EP3744316A4 (fr) Composition pharmaceutique ophtalmique, son procédé de préparation et son application
EP3964518C0 (fr) Inhibiteur de cd73, son procédé de préparation et son utilisation
EP3858833A4 (fr) Dérivé d'aminonordécane, son procédé de préparation et son utilisation
EP4071170A4 (fr) Composition pharmaceutique, son procédé de préparation et son utilisation
EP3777862A4 (fr) Composition de méloxicam, sa préparation et son procédé de préparation et son utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240719

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 471/04 20060101ALI20240715BHEP

Ipc: C07D 413/14 20060101ALI20240715BHEP

Ipc: C07D 405/14 20060101ALI20240715BHEP

Ipc: C07D 403/14 20060101ALI20240715BHEP

Ipc: C07D 401/14 20060101ALI20240715BHEP

Ipc: C07D 241/08 20060101ALI20240715BHEP

Ipc: A61P 7/02 20060101ALI20240715BHEP

Ipc: A61K 31/4425 20060101ALI20240715BHEP

Ipc: C07D 403/10 20060101AFI20240715BHEP